Peptide/Protein Ingredients TRIZ Cases

A buffer-free stabilizer and surfactant system keeps fusion proteins stable at pH 4-8 while reducing aggregation and preserving biological activity.

Multifunctional antibody complexes link tumor and immune cells to kill cancer, induce memory T cells, and lower GVHD risk.

Peptide V2R antagonists use sequence-specific substitutions to block cAMP signaling, improve selectivity, and avoid tolvaptan-linked hepatotoxicity.

Dual CD19-CD20 CAR targeting helps engineered T cells resist exhaustion and improve persistence against B cell malignancies.

Using p80 from the type E botulinum complex, this case shows how intestinal permeability can be increased to improve drug bioavailability without cytotoxicity.

Antigen-reduced transgenic pig donors and non-Gal immune modulation help track and limit cardiac xenograft rejection.

Targeted lectin mutations and dimer formation improve thermostability and protease resistance while lowering viral load in swine.

Cardiac-tropic rAAV delivers functional cMyBP-C to myocardium, restoring contractility and addressing the genetic cause of hypertrophic cardiomyopathy.

Targeted IL-21 amino acid substitutions improve thermal stability and folding while preserving potency for cancer and immune therapies.

C-terminal albumin-binding fusion and stabilizing mutations help alpha-1-antitrypsin resist oxidation and polymerization while extending half-life.

CD45+ leukocytes carry iron-binding drug complexes across the blood-brain barrier to reach deep glioma sites with lower toxicity.

Site-specific albumin conjugation extends urate oxidase half-life and lowers immunogenicity for uric acid-related treatment.

Specific IFN-α2 receptor-binding mutations increase IFNAR1 affinity, boosting anti-HBV activity without cytotoxicity at antiviral doses.

Genetically engineered macrophages expressing MMP9 or MMP12 boost anti-fibrotic matrix breakdown and phagocytosis for fibrotic inflammation.

Targeting p55γ helps prevent aortic dissection by maintaining VSMC contractility and limiting elastic fiber degradation.

CD55 membrane display helps an oncolytic virus resist complement and antibody neutralization, enabling repeated intravenous cancer treatment.

Donut-shaped biodegradable semaglutide microparticles enable 4-week sustained release without initial burst while improving diameter uniformity.

Electron beam treatment cuts viral and microbial contamination in pancreatic enzyme preparations while preserving lipase activity and product potency.

pH-responsive ethylenediammonium alginate beads protect bioactive agents in fish stomachs, then dissolve rapidly in the intestine.

Activated fibroblasts reduce IL-17 production and Th17 generation to help control chronic inflammation in autoimmune and inflammatory disease.

Dual HIS and Strep tags enable efficient affinity purification of bacterial hyaluronidase with high purity, activity, stability, and solubility.

GDF15 polypeptides boost erythropoiesis and hemoglobin, helping treat anemia while reducing reliance on high-dose EPO.

Engineered BCMA-targeting CAR-T cells use an S-derived scFv to improve myeloma cell killing, persistence, and recurrence control.

A fibronectin-coated membrane culture expands UCB-MSCs while preserving proliferation, differentiation, migration, and angiogenic potential.

Combining IL-10 with checkpoint inhibitors restores immune function and improves tumor response in low-mutation, low-PD-L1 cancers.

Engineered CAR polypeptides bind and neutralize TGF-β while converting its suppressive signal into T-cell activation and proliferation.

Targeting the SARS-CoV-2 spike RBD, these peptides block virus-host cell binding to support neutralizing therapy, prevention, and detection.

Targeted 2′-FL and LNFP-I fortification raises nutrient intake for preterm infants without the energy density that can suppress milk volume.

Enterokinase or factor Xa cleaves an engineered activation loop to convert single-chain neurotoxins into purer di-chain forms with fewer impurities.

A recombinant oncolytic HSV co-delivers IL-15 and IL-15Rα in tumors to boost NK and CD8 T-cell killing and support CAR-based therapy.

An ASO linked to a protein-recruiting sequence binds target mRNA to boost translation while avoiding DNA or mRNA delivery limits.

Measuring reduced NMI enables earlier CLAD prediction in lung transplant patients and supports EMT-targeted treatment before irreversible damage.

Chimeric TGFβ receptors let engineered T cells turn suppressive tumor signals into activation, improving function in solid tumors.

DNase therapy degrades extracellular DNA to reduce tumor immunosuppression, boost CD8/NK killing, and limit adverse events.

Gastric-stable bacterial SOD variants retain antioxidant activity in feed, supporting animal growth, immune response, and gut health.

Free carboxyl PLGA or PLA particles improve loading of positively charged proteins while enabling controlled release without harsh encapsulation steps.

Novel anti-GPRC5D and CD3 bispecific antibodies improve target binding and T-cell activation for multiple myeloma treatment.

A collagen-binding scaffold captures EPCs after angioplasty to speed reendothelialization while reducing thrombosis and restenosis.

A stem cell plus cartilage cell-free crush complex guides cartilage differentiation in vivo while reducing off-target cell formation and improving hyaline cartilage repair.

Targeted PYY residue substitutions extend peptide action and improve appetite and metabolic regulation with lower side-effect burden.

Intermittent chaperonin peptide dosing at relapse onset induces ARDS remission without continuous treatment, reducing drug burden and compliance issues.

Protease cleavage in crude cell fractions plus mixed-mode and cation exchange chromatography yields high-purity NGF muteins with reduced nociceptive activity.

Direct in vivo rAAV delivery of codon-optimized PEX1 restores peroxisomal import while avoiding complex ex vivo lentiviral treatment.

Targeted EndoS2 mutations suppress hydrolysis while boosting transglycosylation, enabling efficient homogeneous antibody glycan remodeling.

Specific human plasma fractions with defined protein compositions support muscle regeneration and more standardized treatment of wasting disorders.

Peptides block GM-CSF signaling in microglia to curb macrophage-driven glioma invasion, growth, and therapy resistance.

Local botulinum toxin application increases endometrial blood flow and receptivity to address thin endometrium and repeated implantation failure.